Market Overview

Allergan to Acquire MAP Pharmaceuticals for $25.00/Share

Share:
Related AGN
Valeant CEO On Allegations Against The Company And Future M&A Deals
What Investors Are Expecting Ahead Of Multiple Nektar Therapeutics Catalysts
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 (Fox Business)

Allergan (NYSE: AGN) and MAP Pharmaceuticals (NASDAQ: MAPP)
today jointly announced that they have entered into a definitive merger
agreement whereby Allergan will acquire 100% of the shares of MAP
Pharmaceuticals for a price of $25.00 per share. MAP Pharmaceuticals is
a biopharmaceutical company focused on developing and commercializing
new therapies in Neurology, including LEVADEX®, an orally inhaled drug
for the potential acute treatment of migraine in adults. LEVADEX® is
currently under review with the U.S. Food and Drug Administration (FDA).

The transaction, which has been unanimously approved by the boards of
directors of both companies, will be accomplished pursuant to a cash
tender offer followed by a second step merger. The per share cash

See full press release

Posted-In: News Guidance Management M&A

 

Related Articles (MAPP + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters